SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
494The one thing I always admired with Boger is his dealmaking acumen. He has proveSpekulatius-4/30/2001
493Three cheers! Hip Hip Hooray x 3!scaram(o)uche-4/30/2001
492It is bit shame that today no single SI biofreaks found necessary to write few nMiljenko Zuanic-4/30/2001
491J Pharm Sci 2001 May;90(5):623-35 VX-497: A novel, selective IMPDH inhibitor aMiljenko Zuanic-4/8/2001
490Eur J Neurosci 2001 Mar;13(6):1085-1092 Immunophilin ligands can prevent progrMiljenko Zuanic-4/8/2001
489Hurry up Aventis, with ICE. Before J start playing basketball more often. EuroMiljenko Zuanic-3/16/2001
488VRTX was OVER-valued @ >80, but it is UNDER-valued @ <40. Miljenko [EOMMiljenko Zuanic-3/15/2001
487Thursday March 15, 4:50 pm Eastern Time BusinessWeek Online THE BIOTECH BEAT -- smh-3/15/2001
486Proc. Natl. Acad. Sci. USA, Vol. 98, Issue 5, 2871-2876, February 27, 2001 PhysMiljenko Zuanic-3/3/2001
485>> Could the Vertex drug be the 3rd drug in the Combo? << No, it isscaram(o)uche-2/22/2001
484<<Admittedly, if VRTX or anyone else offers a far better drug than ribavirMiljenko Zuanic-2/22/2001
483I said: <<I do think there is a significant market* in non-responders and IRWIN JAMES FRANKEL-2/22/2001
482<<I do think there is a significant market in non-responders and non-tolerrkrw-2/22/2001
481Hi tuck, You may want to listen to the CC. Link: vrtx.com The PR release: bIRWIN JAMES FRANKEL-2/22/2001
480IJ, I didn't see anything so explicit about VX-497 in this release or any otuck-2/22/2001
479VX-497 It appears the stock is getting hit for a lack of statistical significanIRWIN JAMES FRANKEL-2/22/2001
478Vertex Reports: Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 200tuck-2/22/2001
477Message 15374806nigel bates-2/19/2001
476Wow, solid patent. Guess no lead yet. From website: "Vertex is conductinkeokalani'nui-2/12/2001
475United States Patent 6,183,121 Kim , et al. February 6, 2001 Hepatitis Miljenko Zuanic-2/10/2001
474Tuesday February 6, 5:30 pm Eastern Time Press Release SOURCE: Vertex PharmaceuMiljenko Zuanic-2/6/2001
473Both, imw, but pathway redundancy is for now primary concern. Knock-out mice caMiljenko Zuanic-1/22/2001
472>>cautious is warranted for single caspase inhibitor in neuroprotection<keokalani'nui-1/22/2001
471I think that their target is caspase-3. However, cautious is warranted for singlMiljenko Zuanic-1/21/2001
470Idun's progress with caspase inhibitors. PR doesn't say much. KEYSTONEkeokalani'nui-1/18/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News